TIMM17A

Across TCGA pan-cancer cohorts, TIMM17A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TIMM17A data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TIMM17A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TIMM17A expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

CCRCC, UCEC, and LUAD are the cancer types where TIMM17A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.162	1.000	.024	14	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.356	.022	8	view →
LUAD	OS	Median	All	0.886	0.995	.025	7	view →
HNSC	OS	Median	All	1.000	0.959	.023	4	view →
GBM	OS	Quartile	All	0.681	0.250	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TIMM17A–CCRCC (DFS)

Open the CCRCC breakdown →